OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Status:
Completed
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared
with placebo, in achieving a 100% reduction in urinary incontinence in patients with
overactive bladder (OAB) not properly managed with an anticholinergic.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA